The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients
This study has been completed.
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00524251
First received: August 29, 2007
Last updated: September 16, 2008
Last verified: September 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as in patients who have not implemented lifestyle-adjustments prior to the start of treatment (baseline)
| Condition | Intervention |
|---|---|
|
GERD Quality of Life |
Drug: esomeprazole |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
Resource links provided by NLM:
MedlinePlus related topics:
GERD
Drug Information available for:
Omeprazole
Omeprazole magnesium
Esomeprazole
Esomeprazole Sodium
Esomeprazole magnesium
U.S. FDA Resources
Further study details as provided by AstraZeneca:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with reflux complaints
- 18 years of age
Exclusion Criteria:
- Restrictions as mentioned in the registration text
- H2RA or PPI use in the month prior to inclusion
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00524251
Show 54 Study Locations
Show 54 Study LocationsSponsors and Collaborators
AstraZeneca
Investigators
| Study Director: | A Sellink, MD | AstraZeneca |
| Study Chair: | N van den Berk | AstraZeneca |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00524251 History of Changes |
| Other Study ID Numbers: | N11 |
| Study First Received: | August 29, 2007 |
| Last Updated: | September 16, 2008 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by AstraZeneca:
|
Patients with reflux complaints GERD quality of life lifestyle adjustments |
Additional relevant MeSH terms:
|
Gastroesophageal Reflux Esophageal Motility Disorders Deglutition Disorders Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Omeprazole |
Anti-Ulcer Agents Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013